Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq of YB5 and MCF7 treated with different doses of decitabine

ABSTRACT: RNA-seq was performed after YB5 cells were treated with 1uM decitabine, and MCF7 cells were treated with 100nM decitabine

ORGANISM(S): Homo sapiens

PROVIDER: GSE74251 | GEO | 2017/01/31

SECONDARY ACCESSION(S): PRJNA299580

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Effect of decitabine, carboplatin and their combination on gene expression in the YB5 colon cancer cell line.

Project description:YB5 cell line is a clonal derivative of the SW48 colon cancer cell line that contains a single copy of a green fluorescent protein (GFP) reporter silenced by CpG methylation at its CMV promoter. We treated the YB5 cells with decitabine (5-aza-2’-deoxycytidine), carboplatin and the combination of decitabine plus carboplatin and analyzed the effects of the drugs on gene expression. YB5 cells in the early log phase of growth were seeded at 3.5 million in 20 ml of culture medium in 10 cm diameter tissue culture plates at day 0. The cells were treated with 20 microliters of decitabine (final concentration 25 nM), carboplatin (final concentration 20 uM) or both at days 1, 2, 3 and 4. Control cells were treated with 20 microliters of diluent (DMSO). The cells were harvested at day 6. Total RNA was extracted by TRIZOL, labeled with Cy5 (control cells) or Cy3 (treated cells) and hybridized on Agilent Whole Genome Array (G4112F). Raw data from the Agilent scanner were loess normalized using Bioconductor packages limma and agilp.

2015-09-08 | E-GEOD-66279 | biostudies-arrayexpress

Effect of decitabine, carboplatin and their combination on gene expression in the YB5 colon cancer cell line.

2015-09-08 | GSE66279 | GEO

RNA-seq of YB5 cells treated with epigenetic therapy

Project description:RNA-seq was performed after YB5 cells were treated with S2101, UNC0638, GSK343, depsipeptide alone or in combination with decitabine

2016-12-31 | GSE73966 | GEO

DA Methylation patterns in decitabine treated 786-0 cells

Project description:Genome-wide DNA methylation profiling of 786-0 RCC cells treated with decitabine (100nM and 300nM) or DMSO vehicle. The Illumina Infinium HumanMethylation EPIC BeadChip was used to obtain DNA methylation profiles across approximately 850K CpGs.

2020-06-01 | GSE146179 | GEO

ATAC-seq of YB5 cells treated with HH1

Project description:ATAC-seq was performed after YB5 cells were treated with DMSO or HH1

2018-10-26 | GSE113608 | GEO

RNA-seq of YB5 cells treated with Proscillaridin A

Project description:RNA-seq was performed after YB5 cells were treated with DAC, Proscillaridin A, or the combinatino of the two

2016-11-28 | GSE89154 | GEO

RNA-seq of MCF7 cells treated with epigenetic therapy

Project description:RNA-seq was performed after MCF7 cells were treated with S2101, UNC0638, GSK343, depsipeptide alone or in combination with decitabine

2016-12-31 | GSE74036 | GEO

Transient low-dose decitabine treatment of primary AML samples

Project description:Genome-wide DNA methylation profiling of primary AML samples treated with 100nM decitabine (DAC), cytarabine (AraC), or DMSO. Eight distinct AML samples were grown using an in vitro stromal co-culture system for 4 days and then treated with either DAC, Ara-C or DMSO for 3 days. DNA was prepared for genome-wide methylation analysis with the Illumina Infinium 450k Human DNA methylation BeadChip. DNA from each sample/treatment was analyzed on duplicate arrays.

2012-12-18 | GSE40870 | GEO

RNA-seq of YB5 cells treated with HH1

Project description:RNA-seq was performed after YB5 cells were treated with DAC, HH1 or the combination of the two. RNA-seq was also perfomed after viral transduction using a TET-off dnCDK9 construct

2018-10-26 | GSE104837 | GEO

Homo sapiens

Project description:RNA-seq of YB5 and MCF7 treated with different doses of decitabine

| PRJNA299580 | ENA